New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs

Giuseppe Danilo Norata, Christie M. Ballantyne, Alberico Luigi Catapano

Research output: Contribution to journalArticlepeer-review


Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach.

Original languageEnglish
JournalEuropean Heart Journal
Issue number24
Publication statusPublished - Jun 21 2013


  • Apolipoprotein B
  • Dyslipidaemia
  • PCSK9
  • Pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs'. Together they form a unique fingerprint.

Cite this